Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Inv. presentation
Enochian Biosciences Inc (ENOB) Create: Alert

All | News | Filings
Date FiledTypeDescription
10/11/2023 8-K Quarterly results
10/10/2023 8-K Quarterly results
10/10/2023 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
Docs: "Renovaro Biosciences Appoints Two Finance Industry Experts to Board of Directors"
10/02/2023 8-K Quarterly results
09/29/2023 8-K Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Other Events, Financial Statements and E...
Docs: "Renovaro Biosciences Inc., as Buyer, GEDi Cube Intl Ltd., as Company The Sellers SIGNATORIES Hereto and Yalla Yalla Ltd., in its capacity as Sellers’ Representative Stock Purchase AGREEMENT",
"Source: Renovaro Biosciences Inc."
08/09/2023 8-K Regulation FD Disclosure, Financial Statements and Exhibits  Interactive Data
Docs: "Letter of Intent"
08/07/2023 8-K Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Material Modifications to Rights of Secu...
Docs: "FORM OF COMMON STOCK PURCHASE WARRANT enochian biosciences inc.",
"SUBSCRIBER SIGNATURE PAGE TO SUBSCRIPTION AGREEMENT IN WITNESS WHEREOF, and intending to be legally bound hereby, each Subscriber has caused this Subscription Agreement to be duly executed as of as of the date first set forth above, and by executing this signature page, hereby executes, adopts and agrees to all terms, conditions, and representations contained in the foregoing Subscription Agreement and hereby subscribes for the Securities offered by the Company in the amount set forth below. SUBSCRIBER: Signature Print Name Units : __________ Shares of Series A Convertible Preferred Stock included in the Units: __________ Warrants included in the Units: __________ Purchase Price : $__________ Residence Address: Mailing Address, if different from Residence Address: COMPANY SIGNATURE PAGE TO...",
"PROMISSORY NOTE"
08/07/2023 8-K Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Financial Statements and Exhibits  ...
07/28/2023 8-K Quarterly results
07/11/2023 8-K Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing  Interact...
07/10/2023 8-K Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Financial Statements and Exhibits  ...
Docs: "ARTICLE I STOCKHOLDERS"
06/08/2023 8-K Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "Enochian BioSciences Announces that its Cancer Platform Remains on Track for Trials in Humans Following FDA Review"
05/05/2023 8-K Quarterly results
04/03/2023 8-K Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Financial Statements and Exhibits ...
Docs: "COMMON STOCK PURCHASE WARRANT enochian biosciences inc.",
"Annex A",
"Shareholder Letter"
03/29/2023 8-K Quarterly results
03/13/2023 8-K Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "Enochian BioSciences Achieves Full Compliance with NASDAQ Filing Requirements"
02/23/2023 8-K Entry into a Material Definitive Agreement, Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; T...
Docs: "EXHIBIT A -- NOTICE OF CONVERSION The undersigned hereby elects to convert $_________ Interest and Principal amount of the Note into that number of shares of Common Stock to be issued pursuant to the Conversion of the Note as set forth below, of ENOCHIAN BIOSCIENCES INC., a Delaware corporation according to the conditions of the convertible promissory note of the Company dated as of ____________ ___ , as of the date written below. No fee will be charged to the Holder for any Conversion: Box Checked as to applicable instructions: [ ] The undersigned hereby requests that the Company issue a certificate or certificates for the number of shares of Common Stock set forth below in the name specified immediately below or, if additional space is necessary, on an attachment hereto: ENOCHIAN BIOSCIE...",
"AMENDMENT NO. 3 TO PROMISSORY NOTE This Amendment No. 3 to Promissory Note , dated as of December 30, 2022 , is entered into by and between ENOCHIAN BIOSCIENCES, INC., a Delaware corporation , and PASECO APS . RECITALS",
"SECURITY AGREEMENT",
"Enochian BioSciences Announces Receipt of Notice from Nasdaq Regarding Delayed Filing of Form 10-Q for the Period Ended December 31, 2022"
12/30/2022 8-K Quarterly results
12/16/2022 8-K Quarterly results
11/30/2022 8-K Quarterly results
10/24/2022 8-K Quarterly results
10/21/2022 8-K Quarterly results
10/17/2022 8-K Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "######"
09/23/2022 8-K Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "CEO’ s Letter to Shareholders"
07/06/2022 8-K Quarterly results
07/01/2022 8-K Quarterly results
06/06/2022 8-K Quarterly results
06/02/2022 8-K Quarterly results
05/31/2022 8-K Quarterly results
05/26/2022 8-K Quarterly results
05/24/2022 8-K Quarterly results
05/17/2022 8-K Quarterly results
04/20/2022 8-K Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "Enochian BioSciences Announces the Appointment of Executive Vice President of Research and Development with 25 years of Industry Experience Los Angeles. April 20,2022. Enochian BioSciences . Enochian BioSciences Inc., a company focused on gene-modified cellular and immunotherapies in infectious diseases and cancer, today is announcing the appointment of Dr. François Binette, Ph.D. as Executive Vice President for Research and Development. Dr. Binette brings over 25 years of Advanced Therapy and Regenerative Medicine product development expertise, most recently as Senior VP of Product Development at Lineage Cell Therapeutics where he led multiple innovative allogenic cell therapy programs from discovery to clinical stages and contributed to one of the largest non-cancer cell therapy c..."
04/07/2022 8-K Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "Enochian BioSciences Announces Appointment of Senior Vice President for Clinical Operations with 32 Years’ Experience at Pfizer"
  Next >>

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy